MKI67 and neoplasm: Figure 7C–E, G show that as compared with everolimus alone treatment, co-administration of mitoxantrone and everolimus showed a better therapeutic benefit, as indicated by a significant decrease in the tumor volumes and weights, as well as the proliferative marker Ki67.